GENTLER
13 Dec 2022
Trial Summary
The GENTLER Trial: GenesisCare Epithelial Neoplasia Trial using Lighter dose Extensive field Radiotherapy
Acronym:
GENTLER
ACTRN/NCT /ethics:
ACTRN12620000618954
Scientific title:
GenesisCare Epithelial Neoplasia Trial using Lighter dose Extensive field Radiotherapy
Sponsor / Cooperative group:
–
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | - |
| Age Range | 50 Years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2020-07-27 |
| Anticipated End Date | 2023-03-16 |
Participating Hospitals
| Hospital | GenesisCare |
|---|---|
| Clinical Trial Coordinator | Kimberley Ruxton |
| Kimberley.Ruxton@genesiscare.com | |
| Phone | - |
| Principal Investigator | Dr Andrew Potter |
| Recruitment Status | Recruiting |